Ovid Therapeutics
Ovid Therapeutics' revenue rose 1181.3% to $7 million in fiscal 2025. Its operating margin was −585.2%, up from −10,933.8% a year earlier. Free cash flow was −$38 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ovid Therapeutics does
Ovid Therapeutics is a drug developer with no products on the market. It works on small-molecule medicines for brain disorders in which nerve cells become overactive, such as epilepsy and psychosis. It has in-licensed and developed drug candidates that it hopes will work in new ways.
Its programs are in clinical trials for seizures that resist treatment, rare childhood epilepsies such as tuberous sclerosis complex seizures and infantile spasms, psychosis linked to Parkinson's disease and Lewy body dementia, and schizophrenia. It also has early programs for other forms of psychosis and mood disorders.
Because it has nothing to sell yet, Ovid describes its plan as moving these drug candidates through clinical trials and winning approval. It says it may also earn money from milestone payments and from partnerships with other companies. It competes with other drug developers for the same patients and approvals. It says it intends eventually to sell its own medicines.
Its biggest risks, as it describes them
- It needs more capital to fund its work, and expects to keep losing money.
- Its drug candidates may fail in trials or be denied approval; early results may not predict later ones.
- Patient enrollment in trials can be slow and costly, and trials can be delayed or stopped.
- Its drug candidates may cause side effects that delay or prevent approval.
- Competition from other companies developing medicines for epilepsy and psychosis.
Income statement
Ovid Therapeutics lost money in fiscal 2025: a net loss of $17 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 188 | 129 | 106 | 53 | 90 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 12.9x | 18.8x | 9.6x | 5.3x | 9.0x |
| Quick ratio | 12.9x | 18.8x | 9.6x | 5.3x | 9.0x |
Cash flow
Projections
Project Ovid Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Ovid Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −11,763.0% | −9,854.4% | 652.7% |
| Altman Z'' | −2.95 | −9.05 | 0.80 |
| Accruals ratio | −4.4% | 25.0% | 17.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Ovid Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | 13 | 208 | 2 | 0 | 1 | 7 |
| Revenue growth | — | — | — | — | — | 1,551.6% | −99.3% | −73.9% | 44.4% | 1,181.3% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 10 | 50 | 34 | 42 | 63 | 47 | 25 | 29 | 37 | 26 |
| Operating income | −22 | −65 | −53 | −61 | −81 | 124 | −56 | −59 | −62 | −42 |
| Net income | −22 | −65 | −52 | −60 | −81 | 123 | −54 | −52 | −26 | −17 |
| Diluted EPS (US$) | −2.28 | −3.35 | −2.11 | — | −1.39 | 1.76 | −0.77 | −0.74 | — | — |
| Diluted shares (millions) | 10 | 19 | 25 | — | 58 | 68 | 70 | 71 | — | — |
| Cash flow | ||||||||||
| Cash from operations | −18 | −32 | −46 | −51 | −52 | 119 | −55 | −46 | −56 | −38 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Free cash flow | −18 | −32 | −46 | −51 | −52 | 118 | −56 | −46 | −56 | −38 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 6 | 7 | 5 | 8 | 5 | 7 | 7 | 6 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 52 | 87 | 42 | 77 | — | 188 | 129 | 106 | 53 | 90 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 53 | 90 | 48 | 81 | 76 | 194 | 155 | 144 | 92 | 151 |
| Total liabilities | 4 | 6 | 9 | 11 | 32 | 15 | 23 | 56 | 24 | 20 |
| Shareholders' equity | 49 | 83 | 39 | 70 | 44 | 180 | 132 | 88 | 68 | 131 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −645.4% | 59.6% | −3,696.4% | −15,122.7% | −10,933.8% | −585.2% |
| Net margin | — | — | — | — | −642.3% | 59.0% | −3,604.7% | −13,351.8% | −4,670.1% | −240.1% |
| Free cash flow margin | — | — | — | — | −409.9% | 56.8% | −3,756.6% | −11,689.0% | −9,898.8% | −528.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 1,608.4% | −3,855.8% | −11,763.0% | −9,854.4% | 652.7% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −97.7% | −85.0% | −111.1% | −142.6% | 110.0% | −34.7% | −47.6% | −33.9% | −17.5% |
| Return on assets | — | −91.0% | −75.8% | −94.1% | −103.4% | 90.8% | −31.0% | −35.0% | −22.4% | −14.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |